Safety study of naxitamab infusion for neuroblastoma under modified conditioning re-gimen
- VernacularTitle:改良预处理方式下那西妥单抗治疗神经母细胞瘤安全性研究
- Author:
Zhu JIA
1
;
Deng JUN
1
;
Que YI
1
;
Liu LONGZHEN
1
;
Wu LIUHONG
1
;
Yu WANQI
1
;
Guan HUIJIE
1
;
Wang JUAN
1
;
Lu SUYING
1
;
Sun FEIFEI
1
;
Huang JUNTING
1
;
Song MENGJIA
1
;
Zhen ZIJUN
1
;
Cai RUIQING
1
;
Zhang YIZHUO
1
Author Information
- Publication Type:Journal Article
- Keywords: naxitamab; adverse event; child; neuroblastoma; modified conditioning regimen
- From: Chinese Journal of Clinical Oncology 2024;51(22):1154-1158
- CountryChina
- Language:Chinese
- Abstract: Objective:Glucorticoid therapy has the potential to mitigate immunogical effect of naxitamab. Ketamine is an anesthetic medica-tion and cause weak or shallow breathing. This article is to analyze the effect of modified conditioning regimen with substitution re-mifentanil for ketamine and without glucorticoid therapy on adverse events associated with naxitamab. Methods:Clinical data with naxit-amab infusion under modified conditioning regimen in Sun Yat-sen University Cancer Center between June 2023 and June 2024 were re-trieved to analyze adverse events and risk factors. Results:Overall,seventeen patients underwent 201 infusions. The most frequent adverse events were as follows:neurological pain (all grades) 93.0％,hypertension 55.7％,hypotension 34.8％,respectively. Bronchospasm and hyp-oxia were seen in 3.0％ and 10.9％ infusions,respectively. Fever occurred less frequently in the second cycle of infusion. No patients suspen-ded infusion due to severe adverse event. Conclusions:The infusion of naxitamab is tolerable under the modified conditioning regimen and adverse event is less than expected and controllable.
